Change from baseline to week 8* in Lp(a) for week 24 ACR20, ACR50 and EULAR good/moderate responders and non-responders (safety population)
| Subgroup | Statistic | ADA 40 mg SC q2w, n=162 | TCZ 8 mg/kg IV q4w, n=162 |
|---|---|---|---|
| Lp(a) (mg/dL) change from baseline to week 8 | |||
| ACR20 responders | |||
| n | 79 | 104 | |
| Mean (SD) | –2.5 (18.0) | –8.1 (11.9) | |
| min, max | –102.5, 86.4 | –60.0, 4.8 | |
| ACR20 non-responders | |||
| n | 78 | 52 | |
| Mean (SD) | 0.3 (11.4) | –6.5 (12.1) | |
| min, max | –22.0, 55.2 | –53.6, 21.9 | |
| ACR50 responders | |||
| n | 45 | 76 | |
| Mean (SD) | –3.6 (7.2) | –9.0 (13.0) | |
| min, max | –32.6, 6.3 | –60.0, 4.8 | |
| ACR50 non-responders | |||
| n | 112 | 80 | |
| Mean (SD) | –0.1 (17.2) | –6.2 (10.8) | |
| min, max | –102.5, 86.4 | –53.6, 21.9 | |
| EULAR good/moderate responders | |||
| n | 88 | 125 | |
| Mean (SD) | –2.0 (17.8) | –8.6 (12.6) | |
| min, max | –102.5, 86.4 | –60.0, 4.8 | |
| EULAR non-responders | |||
| n | 69 | 31 | |
| Mean (SD) | –0.0 (10.8) | –3.5 (7.8) | |
| min, max | –22.0, 55.2 | –17.9, 21.9 | |
*Includes only patients with both baseline and week 8 values.
ACR, American College of Rheumatology; ADA, adalimumab; EULAR, European League against Rheumatism; IV, intravenous; Lp(a), lipoprotein (a); q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.